King Minos hall III
King Minos hall III
Hypertension
N.6A. Hypertension
1. Management of hypertension in patients with CKD Georgios Hatzivasiliou
2. Resistant hypertension Vasileios Raptis
3. Use of diuretics in CKD: benefits and risks Eleni Intzevidou
4. Hypertension in dialysis Antonios Zagorianakos
Διαλειμα - Καφές
Breakthrough in Nephrology
N.5A. Changing the status quo in CKD
1. SGLT2 inhibitors: what's new? Dimitrios Vlahakos
2. The place of GLP-1 agonists in clinical practice Petros Kalogeropoulos
3. The place of MRAs in clinical practice Konstantinos Psounis
Cardiovascular morbidity
N.3A. Cardiovascular morbidity in CKD
1. Treatment on hyperlipidaemia: what's new? Ioannis Droulias
2. HIF inhibitors: their place in clinical practice Athena Gompou
3. Update in the management of hyperkalaemia Evdokia Efthymiou
General assembly
N.3A. Cardiovascular morbidity in CKD
1. Treatment on hyperlipidaemia: what's new? Ioannis Droulias
2. HIF inhibitors: their place in clinical practice Athena Gompou
3. Update in the management of hyperkalaemia Evdokia Efthymiou
Close
Approved by:
Participants: